Stock PHIO PHIO PHARMACEUTICALS CORP.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Phio Pharmaceuticals Corp.

Equities

PHIO

US71880W4024

Market Closed - Nasdaq
Other stock markets
 21:30:00 03/05/2024 BST 		5-day change 1st Jan Change
0.8197 USD +5.67% Intraday chart for Phio Pharmaceuticals Corp. +16.10% +7.86%
04-22 Phio Pharmaceuticals Corp. Presents New Data About Its Lead Clinical Product Candidate, PH-762 CI
04-16 Phio Pharmaceuticals Announces Upcoming Presentations at the 81st Annual Meeting of the Society for Investigative Dermatology CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Phio Pharmaceuticals Corp. Presents New Data About Its Lead Clinical Product Candidate, PH-762
Phio Pharmaceuticals Announces Upcoming Presentations at the 81st Annual Meeting of the Society for Investigative Dermatology
Phio Pharmaceuticals Corp. Reports Earnings Results for the Full Year Ended December 31, 2023
Phio Pharmaceuticals Corp. Presents Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies
Phio Pharmaceuticals Corp. Announces Addition of Clinical Trial Sites At Banner Md Anderson Cancer Center, the George Washington University, and Integrity Research
Phio Pharmaceuticals Secures Patent for Compounds Treating Age Related Skin Disorders
Phio Pharmaceuticals Corp. Announces Patent Granted by Uspto, Strengthening the Company's Intellectual Property Position in Treating Aging Skin and Skin Disorders
Phio Pharmaceuticals Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Phio Pharmaceuticals Corp. Announces First US Patient Enrolled in Phase 1B Clinical Trial with Intratumoral PH-762 anti-PD-1 Therapy for Treatment of Skin Carcinomas
Phio Pharmaceuticals Shares Rise After Data Shows Intasyl Compound Enhances Tumor Control
Phio Pharmaceuticals Corp. Announces the Presentation of New Preclinical Data At the 38Th Annual Meeting of the Society for Immunotherapy of Cancer
Top Premarket Decliners
Top Midday Gainers
Phio Pharmaceuticals Corp. Presents New Data for Targeting of BRD4 with its INTASYL Compound PH-894
Phio Pharmaceuticals Corp. Announces Dosing of First Patient in Collaborative Clinical Trial with Agonox, Inc. and Providence Cancer Institute
Phio Pharmaceuticals Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Phio Pharmaceuticals Completes $4 Million Securities Offering
Phio Pharmaceuticals to Raise $4 Million From Securities Offering; Shares Fall
Sector Update: Health Care Stocks Weaker Late Thursday
Sector Update: Health Care Stocks Dropping Thursday Afternoon
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. PHIO Stock
  4. News Phio Pharmaceuticals Corp.
  5. Other languages